For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 6,464,371 | |||
| Research and development | 11,514,123 | |||
| Total operating expenses | 17,978,494 | |||
| Loss from operations | -17,978,494 | |||
| Interest income | 437,931 | |||
| Other income, net | 421,125 | |||
| Net loss | -17,119,438 | |||
| Basic EPS | -1.57 | |||
| Diluted EPS | -1.57 | |||
| Basic Average Shares | 10,898,175 | |||
| Diluted Average Shares | 10,898,175 | |||
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)